The Centers for Medicare & Medicaid Services has posted a FAQ on the Coronavirus Aid, Relief, and Economic Security Act requirement that providers of COVID-19 diagnostic tests make public the cash price for the tests on their website during the public health emergency.

The FAQ also notes that under the CARES Act and Families First Coronavirus Response Act, group health plans generally must reimburse providers of COVID-19 diagnostic tests at the negotiated rate or cash price, and cover certain COVID-19 diagnostic testing without cost sharing, prior authorization or other medical management requirements during the public health emergency.

Related News Articles

Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…